Schmitz named SRNT fellow
The Society for Research on Nicotine and Tobacco (SRNT) has named Joy Schmitz, PhD, professor and Louis A. Faillace, MD, Chair in the Department of Psychiatry and Behavioral Sciences, as a member of its 2023 Fellowship class.
The status of Fellow of the SRNT is a distinction conferred by the Society on members in recognition of outstanding contributions to the field of nicotine and tobacco research, and of service to SRNT. Launched in 2016, nominees are judged on their research, service to the field, and service and/or demonstrated involvement in the society.
“It is a true honor to be awarded fellowship status in SRNT,” Schmitz said. “Being a member of this Society has allowed me to pursue research on nicotine and tobacco, and most importantly, translate new knowledge into more effective ways to treat tobacco use. I am humbled and grateful to know that my contributions over the years have had a substantive impact on the field.”
Schmitz is the director of the Center for Neurobehavioral Research on Addictions, where she has developed a longstanding research program on the development and evaluation of behavioral treatments and combinations of behavioral therapies and pharmacotherapies for substance use disorders. Her research has been continuously funded since 1995 and has resulted in over 120 publications.
Schmitz is a founding member for the Society for Research on Nicotine and Tobacco and is an associate editor for Nicotine and Tobacco Research the journal of the SRNT. She also serves as a member of the American Psychological Association and the College of Problems on Drug Dependence and has held roles on NIH study sections and special emphasis panels.
At UTHealth Houston, Schmitz earned the Women Faculty Forum Clinical Excellence Award in 2016 and the UTHealth Houston President’s Award for Mentoring Women in 2003.
Schmitz completed her PhD in clinical psychology in 1988 at Auburn University in Montgomery, before a residency in that subject at the University of Mississippi Medical Center V.A. Medical Consortium.